Trial Profile
A Phase I Dose Escalation Study of RAD001 in Combination With Chemotherapy and Radiation in Patients With NSCLC.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2012
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Everolimus (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 03 Jul 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Jul 2012 Actual patient number is 3 according to ClinicalTrials.gov.
- 03 Jul 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.